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Abstract
Background: Recurrence prediction of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients undergoing
liver transplantation (LT) present a great challenge because of a lack of biomarkers. Genetic variations play an important role
in tumor development and metastasis.
Methods: Oligonucleotide microarrays were used to evaluate the genetic characteristics of tumor DNA in 30 HBV-related
HCC patients who were underwent LT. Recurrence-related single-nucleotide polymorphism were selected, and their
prognostic value was assessed and validated in two independent cohorts of HCC patients (N=102 and N=77), using
pretransplant plasma circulating DNA. Prognostic significance was assessed by Kaplan-Meier survival estimates and log-rank
tests. Multivariate analyses were performed to evaluate prognosis-related factors.
Results: rs894151 and rs12438080 were significantly associated with recurrence (P=.003 and P=.004, respectively).
Multivariate analyses demonstrated that the co-index of the 2 SNPs was an independent prognostic factor for recurrence
(P=.040). Similar results were obtained in the third cohort (N=77). Furthermore, for HCC patients (all the 3 cohorts)
exceeding Milan criteria, the co-index was a prognostic factor for recurrence and survival (P,.001 and P=.002, respectively).
Conclusions: Our study demonstrated first that genetic variations of rs894151 and rs12438080 in pretransplant plasma
circulating DNA are promising prognostic markers for tumor recurrence in HCC patients undergoing LT and identify a
subgroup of patients who, despite having HCC exceeding Milan criteria, have a low risk of post-transplant recurrence.
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Introduction
Hepatocellular carcinoma (HCC) is a malignant tumor
responsible for approximately 600,000–700,000 deaths worldwide
and is becoming more prevalent not only in Southeast Asia and
Africa, but also in western countries [1,2]. Because of high
infection rates with hepatitis B virus (HBV), 55% of world’s HCC
cases occur in China [3]. Despite improvements in surveillance
and clinical treatment strategies, the prognosis of HCC remains
dismal [4]. Tumor resection is the first treatment choice for early-
stage HCC. However, recurrence and metastasis after curative
resection remain the main factors that decrease survival [5].
Moreover, for patients with multifocal HCC or advanced cirrhosis,
resection is not always feasible. Liver transplantation (LT) removes
both tumors and underlying liver cirrhosis; therefore, it plays an
important role in HCC management. However, the scarcity of
liver donors has limited its clinical application. Thus, risk
estimation of post-transplant tumor recurrence and metastasis is
an essential element in selecting HCC patients for LT.
Hepatocarcinogenesis is characterized by accumulation of
genetic alterations including chromosomal rearrangements, acti-
vation of oncogenes, and inactivation of tumor suppressor genes
[6]. Our previous study demonstrated that genes favoring HCC
metastasis progression are initiated relatively early in primary
tumors [7]. Genomic information may provide better insights into
HCC behavior and patient-directed therapy [8–11]. These
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associated with HCC recurrence and metastasis, which could be
valuable for prediction of prognosis and selection of subsequent
treatment. Single-nucleotide polymorphisms (SNPs) may represent
the most common genetic variations in the human genome. As
genetic markers, SNPs have several advantages over microsatellite
sequence repeats, including abundance (one in every 750–
1000 bp), stability, and suitability for high-throughput analysis
[10,12]. Microarray-based high-density SNP analysis makes a
reproducible and rapid determination of genome-wide alterations
possible. Some SNPs exhibit different allele frequencies between
tumor and normal tissues [12]. Therefore, studies on SNPs
genotyped from tumor DNA may help clarify the biological
importance of genetic variations in the tumor genome. However,
tumor tissue can only be obtained after surgery or from invasive
biopsy.
Detection of biomarkers from peripheral blood obtained before
surgery is more convenient and more applicable for prognosis
prediction than from post-surgery tissue samples. Tumor-derived
DNA has been detected in the plasma or serum of cancer patients
[13–15]. A recently published study demonstrated that circulating
DNA from tumor patients can be used to assess tumor dynamics
[16,17]. Thus, circulating DNA may be a good target to study,
instead of DNA from tumor tissues, for its accessibility, simple
manipulation, and available prognostic information before surgery
[18]. Here, we detected genetic variations associated with
prognosis in pretransplant plasma circulating DNA and evaluated
the predictive value for post-transplant recurrence and metastasis
in HBV-related HCC patients undergoing LT.
Materials and Methods
Ethics statement
The study protocol was approved by The Research Ethics
Committee of Zhongshan Hospital, Fudan University. Informed
written consent was obtained according to the Declaration of
Helsinki.
Patients and specimens
The LT program of Zhongshan Hospital started in 2001. At the
beginning, the indication of LT in our hospital was quite expanded
(without macrovascular invasion, lymph node invasion and
extrahepatic metastasis). Through the year 2007, we started to
use Shanghai criteria for selecting HCC patients for LT (HCC
patients with a solitary lesion , or =9 cm in diameter, no more
than three lesions with the largest , or =5 cm, a total tumor
diameter , or =9 cm without macrovascular invasion, lymph
node invasion and extrahepatic metastasis [19]). The inclusion
criteria for this study were as follows: 1) HBV background and
distinctive HCC diagnosis by pathology; 2) full follow-up and
clinicopathological data; and 3) well-preserved formalin-fixed,
paraffin-embedded (FFPE) tissues or plasma samples extracted
before LT. 4) without macrovascular invasion, lymph node
invasion and extrahepatic metastasis. Our previous study and
other literature reported that mTOR-based immumosuppression
(Rapamycin) may improve the overall survival of HCC patients
after LT [20,21]. Thus, the present study excluded patients treated
with mTOR-based immumosuppression and only included those
patients using FK-506 (tacrolimus). Two hundred and nine
patients were included in this study. All patients were received
deceased donor liver transplantation. After LT, patients were
followed with regular surveillance for recurrence or metastasis by
chest radiograph, abdominal ultrasonogram, computed tomo-
graphic (CT) and AFP level measurement every 2 months in the
first year, and at least every 3–4 months thereafter. A diagnosis of
recurrence was based on typical imaging appearanceon and/or an
elevated AFP level. Among the 209 patients included in the study,
91 developed HCC recurrence and 86 patients died (68 patients
died of HCC recurrence and 18 died of transplantation-related
complications). We use Lamivudine (100 mg/day) or Entecavir
(0.5 mg/day) in combination with hepatitis B immunoglobulin
(HBIG) to prevent HBV reactivation after LT. All patients were
given 2400 IU HBIG intravenously in LT, followed by posttrans-
plant 400 IU HBIG i.m. tid. until serum HBsAg became negative,
and the titer of HBsAb is more than 150 IU/l. Thereafter,
lamivudine or entecavir continued to use in the lifetime, and
HBIG dosage was adjusted to keep the titer of HBsAb .150 IU/l.
We designed our study referring to REMARK guidelines for
reporting prognostic biomarkers in oncology [22]. The study
design is shown in Figure 1. The clinicopathological characteristics
of three cohorts of HCC patients are summarized in Table S1.
Peripheral blood and FFPE tumor tissues were collected for DNA
extraction (Supplemental Text S1).
Microarray hybridization and genotyping
Tumor DNA was extracted from 30 FFPE tumor tissues
(Discovery Set). Hybridization was performed on Affymetrix
GeneChip Human Mapping SNP6.0 using the Human mapping
SNP6.0 assay kit (Affymetrix Inc., Santa Clara, CA, USA). Plasma
circulating DNA was genotyped using the MassARRAY system
(Sequenom Inc., San Diego, CA, USA) and matrix-assisted laser
desorption ionization-time of flight (MALDI-TOF) mass spec-
trometry (Supplemental Text S1).
Statistical analysis
The Cochran-Armitage trend test was used to assess alleles
associated with recurrence after LT. Unsupervised hierarchical
clustering analysis was performed using Cluster software (version
3.0) and TreeView software (version 1.0.13). The Spearman rank
test and Fisher’s exact test were used to evaluate clinicopatholog-
ical correlations. We used time to recurrence as the primary
endpoint. Overall survival and tumor-related death were used as
the secondary endpoint. Time to recurrence (TTR), Overall
survival (OS) and tumor-related death were analyzed using the
Kaplan–Meier method and the log-rank test. OS was defined as
the interval between LT and death or the last observation. The
data were censored at the last follow-up for living patients. TTR
was measured from the date of LT until the detection of recurrent
tumor or the last follow-up assessment. The data were censored for
patients without tumor recurrence. Tumor-related death was
defined as time from operation to HCC-related death. Patients
alive at the end of follow-up were censored. Multivariate analysis
using Cox proportional hazards model was used to evaluate
prognosis-related factors. Data were analyzed using the statistical
package SPSS 16.0 (SPSS Inc., Chicago, IL, USA). A statistical
significance was set at P,.05. Receiver operating characteristic
(ROC) curve analysis was used to determine the predictive value
for tumor recurrence. All microarray data were registered into
NCBI’s Gene Expression Omnibus (GEO) database (http://www.
ncbi.nlm.nih.gov/projects/geo/). (Accession number GSE29667).
Results
Microarrays
Call rates ,65% were often associated with highly degraded
DNA from FFPE samples [23]. After strict quality control before
hybridization, all 30 samples passed the call rate threshold of 65%
(average, 74.4%; range, 72.1–78.1%) and were subjected to
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rates ,90%. After this filtration, 230,802 SNPs were included for
further analysis. We used the Cochran-Armitage trend test to
assess alleles associated with recurrence or metastasis after LT. We
identified 1272 SNPs with P,.01, and among these, 30 SNPs
demonstrated P,.001 (Figure S1C). Hierarchical clustering was
performed based on the 1272 SNPs (Figure S2A) and the top 30
SNPs (Figure S2B). The top 30 SNPs, rather than the 1272 SNPs,
could separate recurrence (high-risk group) from non-recurrence
patients (low-risk group). The low-risk group had longer OS and
TTR than the high-risk group (Figure S2C and 2D).
Genotyping of plasma circulating DNA
To study the concordance between plasma circulating DNA
and FFPE tumor DNA, we genotyped the top 30 SNPs in plasma
circulating DNA from Discovery Set using the MassARRAY
system. rs8059833 failed in PCR amplification and rs860056 was
excluded because of low call rate (,90%) and finally we
successfully genotyped 28 SNPs in plasma circulating DNA. Our
results revealed that plasma circulating DNA and FFPE tumor
DNA have a high concordance (98.2%). Plasma circulating DNA
extracted from 102 patients in Training Set was genotyped for the
28 SNPs. As shown in Table S2, we calculated the allele
frequencies between the recurrence and non-recurrence groups
using Haploview software (vesion 4.1). We found that the minor
alleles at rs894151 and rs12438080 were significantly associated
with recurrence and metastasis in HCC patients after LT (P=.033
and P=.001, respectively. Table S2).
Clinicopathological characteristics and correlation with
rs894151 and rs12438080
The two-year and four-year survival rates for Training Set
(N=102) were 58.6%, 48.5%, and the two-year and four-year
recurrence rates were 36.3%, 45.1%, respectively. The genotype
frequencies at rs894151 were 67.6% (69/102) for AA, 29.4% (30/
102) for AG, and 2.9% (3/102) for GG. The genotype frequencies
at rs12438080 were 47.1% (48/102) for AA, 47.1% (48/102) for
AC, and 5.9% (6/102) for CC. Because of the low frequency of the
minor allele homozygote at rs894151 and rs12438080 (3/102 and
6/102, respectively), we combined the heterozygote and minor
allele homozygote patients as one group. We divided patients into
two groups by rs894151 (AA and AG/GG). Similarly, patients were
divided into two groups by rs12438080 (AA and AC/CC). We found
that patients with AG/GG at rs894151 have larger tumor sizes,
increased tumor number and higher probability of microvessel
invasion (P=.027, P=.012 and P=.038, respectively), while
younger age and worse tumor differentiation were associated with
AC/CC at rs12438080 (P=.010 and P=.020, respectively; Table
S3).
Prognostic significance of rs894151 and rs12438080
Univariate analysis revealed that patients with AG/GG at
rs894151 or AC/CC at rs12438080 were significantly associated
with a decreased OS (P=.011and P=.038, respectively; Figure 2G
and 2H) and TTR (P=.003 and P=.004, respectively; Figure 2D
and 2E). Patients with more minor alleles showed shorter TTR
and OS (Figure S3, Table S4 and S5). Other unfavorable
predictors for OS were pre-LT treatment, tumor size.5 cm,
multiple tumor nodes, and microvessel invasion (P=.050, P,.001,
P=.003, and P,.001, respectively). Tumor size, tumor number,
tumor encapsulation, and microvessel invasion also had prognostic
significance for TTR (P,.001, P=.015, P=.011, and P,.001,
respectively; Table 1). Multivariate analyses demonstrated that
rs12438080 was an independent prognostic factor for TTR
(P=.042) rather than OS, while rs894151 was not an independent
prognostic factor for TTR or OS (P=.382 and P=.935,
respectively; Table 1).
Chi-square tests revealed no correlation between rs894151 and
rs12438080 (P=.469). To increase predicting power, we combined
the two SNPs as a co-index. We divided patients into two groups
Figure 1. Study design. Discovery Set consisted of 30 patients randomly selected from recurrence patients and non-recurrence patients. Training
Set consisted of 102 consecutive patients from January 2004 to December 2006, while Validation Set comprised 77 consecutive patients from January
2007 to June 2008. Thirty tumor DNA samples randomly selected from the recurrence and non-recurrence groups were hybridized on SNP
microarrays. Signatures associated with tumor recurrence were selected and validated in circulating DNA using two other independent patient
cohorts.
doi:10.1371/journal.pone.0026003.g001
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patients with genotype AA at both rs894151 and rs12438080;
group II: patients with allele G at rs894151 and/or C at
rs12438080). Multivariate analyses demonstrated that the co-index
(rs894151/rs12438080), tumor size, and microvessel invasion were
independent prognostic factors for TTR (P=.040, P=.008, and
P=.006, respectively), while tumor size and microvessel invasion
were independent prognostic factors for OS (P=.042 and
P=.028, respectively; Table 1).
Validation
We validated the prognostic value of the co-index of rs894151
and rs12438080 in another independent cohort of 77 HBV-related
HCC patients who undergoing LT (Validation Set) with results
similar to those in Training Set. Patients with genotype AA at both
rs894151 and rs12438080 had a longer TTR than patients with
allele G at rs894151 and/or C at rs12438080. In multivariate Cox
proportional hazards analyses, the co-index was still an indepen-
dent predictor of TTR (P=.001; Table S6).
ROC analysis
ROC curve analysis were performed (N=209) to evaluate the
predictive power for recurrence. It showed that the predictive
power of the co-index [area under the curve (AUC) =0.788] was
significantly higher than that of rs894151 (AUC=0.683,
P=0.033), rs12438080 (AUC=0.679, P=0.027), tumor number
Figure 2. Prognostic significance assessed using Kaplan–Meier survival estimates and log-rank tests stratified by rs894151 (D, G),
rs12438080 (E, H), and the co-index of the two factors (F, I). A, B, and C show the frequency distributions of genotypes in the non-recurrence
and recurrence groups with the p-value calculated by chi-square test. *B represents a minor allele. Patients were divided into two groups by the co-
index: patients with AA at both rs894151/rs12438080 and patients with minor allele(s).
doi:10.1371/journal.pone.0026003.g002
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P,0.001). Tumor size (AUC=0.699) and microvessel invasion
(AUC=0.717) also had lower AUC when compared with the co-
index, but the differences were not reach statistical significance
(P=0.066 and P=0.136 respectively, Figure 3 and Table S7).
Milan criteria and the co-index of rs894151 and
rs12438080
Among the 209 patients of the three cohorts, 94 met and 115
exceeded Milan criteria [24]. The Clinicopathological character-
istics of patients exceeding Milan criteria were summarized in
table S8. The three-year recurrent rates for patients within Milan
criteria and exceeding Milan criteria were 12.3% and 67.3%. The
survival rates were 83.8% and 40.6% respectively. We stratified
the patients as within or beyond Milan criteria to evaluate the
prognostic value of the co-index (rs894151/rs12438080). The log-
rank test indicated that the co-index can be a novel predictor of
recurrence regardless of Milan criteria (Figure 4A and 4D;
Table 2). The co-index of the two SNPs (rs894151/rs12438080)i n
pretransplant plasma circulating DNA identified a subgroup of
HCC patients with a low risk of post-transplant recurrence, despite
having HCC beyond Milan criteria (Figure 4E). We also
performed analysis of the co-index in patients within or exceeding
UCSF criteria (Supplemental Text S1). The log-rank test indicated
that, in patients exceeding UCSF criteria, the co-index of two
SNPs was also associated with TTR and OS (Table S9). The
results were similar to those in patients within UCSF (Table S10).
Discussion
As a radical treatment for HCC, LT has many advantages over
resection such as simultaneously curing HCC and the underlying
cirrhosis in a single surgery. However, tumor recurrence and
metastasis after LT remain the main obstacles for long-term
survival. To achieve a low recurrence rate and reasonable
distribution of limited donors, meticulous evaluation of the
prognosis in recipients is crucial [25]. However, conventional
prognostic factors for HCC patients are limited to clinicopatho-
logical parameters. Including Milan criteria, most LT indications
for HCC patients focus on the tumor size, number of tumor
nodules, and the absence of macroscopic vascular invasion or
lymph nodes [24,26,27]. Efforts to identify more accurate
prediction algorithms have revealed that tumor size and number
are imperfect surrogates for predicting the metastatic potential of
HCC [28]. Increasingly, more attention is being given to
biological tumor markers for insights into HCC behavior. Studies
on epigenetics [29–31], gene expression [32–35], and proteomics
[36,37] are beginning to yield potentially useful information.
Schwartz et al [28] reported that analysis of allelic imbalance (AI)
of nine microsatellites may extend Milan criteria without
increasing tumor recurrence after LT. Wu et al [38] found Histone
Deacetylase 3 could serve as a biomarker for tumor recurrence
following LT in HBV-Associated HCC. Our previous study
demonstrated that overexpression of Capn4 in HCC tissues was
associated with tumor invasion and metastasis in HCC patients
after LT [39]. In these studies, all the samples used were obtained
from tumor tissues that were only available after surgery.
Therefore, prognosis biomarker studies in preoperative plasma
or serum are urgently needed.
A small amount of circulating DNA can be detected in the
plasma of healthy individuals. The levels of circulating DNA are
elevated in cancer patients and are associated with poor prognosis
[18,40,41]. Many studies suggested that the elevated circulating
DNA of cancer patients was from apoptotic and necrotic tumor
cells [18,42]. Our previous study showed that circulating DNA
extracted from the plasma of HCC patients displayed neoplastic
Table 1. Univariate and Multivariate analyses of factors associated with survival and recurrence in Training Set.
OS TTR
Univariate Multivariate Univariate Multivariate
Factors HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Gender (male versus female) 0.669(0.241–1.855) .440 NA 1.185(0.287–4.891) .814 NA
Age ($50 years versus ,50 years) 0.870(0.507–1.491) .612 NA 0.757(0.423–1.354) .348 NA
Child-Pugh (B/C versus A) 1.291(0.725–2.299) .385 NA 0.791(0.440–1.423) .434 NA
Differentiation (III/IV versus I/II) 1.435(0.836–2.463) .190 NA 1.571(0.879–2.808) .127 NA
AFP ($200 ng/ml versus ,200 ng/ml) 0.914(0.529–1.578) .746 NA 1.086 (0.608–1.941) .780 NA
Encapsulation (none versus complete) 1.331(0.774–2.286) .301 NA 2.183(1.199–3.976) .011 1.527(0.827–2.819) .176
Pre-LT treatment (yes versus no) 1.722(1.001–2.962) .050 1.438(0.820–2.524) .205 1.431(0.793–2.580) .234 NA
Tumor size (.5 cm versus #5 cm) 3.369(1.821–6.234) ,.001 2.078(1.025–4.214) .042 4.236(2.138–8.394) ,.001 2.998(1.334–6.733) .008
Tumor number (multiple versus single) 2.439(1.352–4.401) .003 1.566(0.800–3.065) .190 2.150(1.159–3.988) .015 1.131(0.538–2.379) .746
Microvessel invasion (yes versus no) 3.495(1.862–6.562) ,.001 2.219(1.088–4.525) .028 4.831(2.384–9.787) ,.001 2.843(1.341–6.027) .006
rs894151 (AG/GG versus AA) 2.062(1.182–3.596) .011 1.026(0.549–1.920) .935 2.483(1.374–4.486) .003 1.333(0.700–2.538) .382
rs12438080 (AC/CC versus AA) 1.805(1.034–3.150) .038 1.425(1.798–2.546) .231 2.560(1.360–4.819) .004 1.951(1.025–3.716) .042
rs894151/rs12438080 (AB/BB
1 versus AA) 3.357(1.577–7.146) .002 2.032(0.878–4.704) .098 5.137(2.022–13.050) .001 2.791(1.048–7.436) .040
Abbreviations: OS, overall survival; TTR, time to recurrence; HR, hazard ratio; CI, confidence interval; LT, liver transplantation; AFP, alpha-fetoprotein; NA, not adopted.
The prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. In multivariate analysis variables were adopted for their prognostic
significance by univariate analysis with enter-stepwise selection (p,.05) and the co-index of rs894151/rs12438080 was analyzed when both SNPs were excluded.
1AB/BB
represents patients with minor allele(s) at rs894151 and/or rs12438080. Pre-LT treatment, Tumor size, Tumor number, Microvessel invasion and rs894151/rs12438080
were adopted for Cox analysis for OS. While, Encapsulation, Tumor size, Tumor number, Microvessel invasion and rs894151/rs12438080 were adopted for Cox analysis for
TTR.
doi:10.1371/journal.pone.0026003.t001
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prognostic parameters by receiver operating characteristic (ROC) curves (A). The areas under the curve (AUCs) with 95% CI are shown in B
(*p,.05, compared with the co-index). The details for AUC and 95% CI are also shown in Table S7.
doi:10.1371/journal.pone.0026003.g003
Figure 4. The relationship of the co-index (rs894151/rs12438080) in patients within Milan criteria (upper panel) and exceeding Milan
criteria (lower panel). Time to recurrence of the co-index (rs894151/rs12438080) in patients within Milan criteria (A) and exceeding Milan criteria
(D). The prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. B, E, The recurrences in patients with AA at
both SNPs were 0/44 (within Milan criteria) and 8/26 (exceeding Milan criteria). In patients with a minor allele, the recurrences were 16/50 (within
Milan criteria) and 67/89 (exceeding Milan criteria). C, F, Frequency distributions of genotypes in non-recurrence and recurrence patients. The p-value
was calculated by chi-square test.
doi:10.1371/journal.pone.0026003.g004
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called BEAMing (beads, emulsion, amplification, and magnetics)
to detect colorectal cancer-related genetic variations in circulating
DNA and found that the genetic alterations could be used to
monitor tumor dynamics in colorectal cancer patients undergoing
surgery or chemotherapy. In this study, we tried to screen genetic
variations in pretransplant plasma circulating DNA to identify
promising biomarkers that are associated with tumor recurrence
after LT. First, we used plasma circulating DNA for microarray
hybridization, but the concentration and quantity did not meet the
QC required for microarrays. Whole-genome amplification
(WGA) offers new possibilities for genetic studies where limited
DNA samples have been collected. We succeeded in harvesting
sufficient DNA though WGA. However, the amplified plasma
circulating DNA generated poor-quality array data, yielding a
result similar to that in a previous report [44]. Therefore, we used
FFPE tumor DNA for chip hybridization, then validated candidate
SNPs in plasma circulating DNA using MALDI-TOF mass
spectrometry. High concordance (98.2%) between FFPE tumor
DNA and plasma circulating DNA was confirmed by our result.
We identified two novel SNPs (rs894151 and rs12438080)
located in 8q22 and 15q26 from plasma circulating DNA that
were associated with HCC recurrence after LT and validated
using another independent cohort of patients. The TTR was
negatively associated with the number of minor alleles at rs894151
and rs12438080 (G at rs894151 and C at rs12438080). However,
HCC is a polygenic, complex disease caused by the interaction of
many genetic and environmental factors [45]. Variations in any
one gene in the polygenic pathway may have a small effect on
tumor progression. Therefore, we used the co-index—a combi-
nation of the two SNPs (rs894151 and rs12438080)—to increase
the predictive power of SNPs. Multivariate analyses demonstrated
that the co-index was an independent prognostic factor for
recurrence. ROC analysis also showed that the predictive power of
the co-index was more robust than that of any single SNP. To our
knowledge, the present study is the first one to evaluate the
prognostic value of genetic variations in pretransplant plasma
circulating DNA in HCC patients undergoing LT.
The co-index of rs894151and rs12438080 was an independent
prognostic factor for TTR (P=.040) but not for OS (P=.098),
which may be attributed to the complexity of underlying factors
for post-transplant survival. Besides HCC recurrence, other long-
term problems such as immunosuppression-related and tech-
nique-related complications, as well as organ rejection, are also
important prognostic factors which may cause mortality. In order
to decrease the effect of these factors on survival, we used the
endpoint of tumor-related death for further analysis. We found
that the co-index of rs894151 and rs12438080 was an
independent prognostic factor for tumor-related death (Table
S11).
Previous studies reported several recurrence-associated factors
for HCC patients. Nucleotide analogs may reduce the risk of
HBV-related HCC development and prevent recurrence after
resection [46,47]. Active replication of HBV may initiate
malignant transformation through a direct carcinogenic mecha-
nism by increasing the probability of viral DNA insertion in or
near proto-oncogenes, tumor-suppressor genes [48,49]. However,
new tumors developing from noncirrhosis liver graft need
relatively long period. The main aim of administration of
nucleoside analogues was to prevent function loss of liver graft,
which was caused by HBV reactivation. Further studies that
include a larger number of patients and a longer follow-up period
are necessary to assess the benefits of nucleoside analogues for
preventing long-term HCC recurrence after LT. Des-gamma-
carboxyprothrombin (DCP), also known as the protein induced by
vitamin K absence or antagonist II (PIVKA-II), is reported to be
an effective tumor marker for HCC. This tumor marker is
currently confirmed in Japan, Korea and Indonesia, while many
studies have been performed worldwide. Fujiki et al [50] reported
superiority of DCP and AFP over preoperative tumor size or
number for predicting recurrence after living donor liver
transplantation. Unfortunately, DCP detection is unavailable yet
in our hospital. This restricted our ability to get the pre-LT DCP
data of the studied patients. The prognostic value of the two SNPs
in combination with DCP will be the next phase of our study.
Milan criteria have been accepted worldwide and the outcomes
of HCC patients within Milan criteria were similar to that of
patients undergoing LT without HCC. However, the dichotomous
yes/no nature of Milan criteria has been challenged for being too
strict [27,51,52], some patients with tumors exceeding Milan
criteria are also potentially curable by LT [26–28,51,52]. In the
present study, for those patients exceeding Milan criteria, we
found the co-index of rs894151 and rs12438080 also acted as a
prognostic factor for recurrence (P,.001; Figure 4D and Table 2).
The co-index may be used as a tool to identify patients with AA at
both rs894151 and rs12438080 who, despite having HCC beyond
Milan criteria, have an acceptable outcome profile (Figure 4E).
Therefore, incorporation of tumor genetic variations into selection
Table 2. Kaplan-Meier survival estimates and log-rank tests of factors associated with TTR and OS in patients exceeding Milan
criteria.
Factors TTR OS
HR (95% CI) P HR (95% CI) P
Pre-LT treatment (yes versus no) 1.016 (0.646–1.598) .946 1.083 (0.675–1.737) .741
Child-Pugh (B/C versus A) 1.178 (0.774–1.864) .485 0.175(0.726–1.900) .512
AFP ($200 ng/ml versus ,200 ng/ml) 1.134 (0.721–1.784) .587 1.070(0.668–1.717) .777
Differentiation (III/IV versus I/II) 1.245 (0.789–1.963) .346 1.454(0.906–2.333) .121
Encapsulation (none versus complete) 1.336 (0.844–2.115) .216 0.817(0.510–1.311) .403
Microvessel invasion (yes versus no) 2.975 (1.786–4.954) ,.001 2.916(1.679–5.064) ,.001
rs894151/rs12438080 (AB/BB
1 versus AA) 4.238 (2.021–8.886) ,.001 3.244(1.546–6.805) .002
1AB/BB represents patients with minor allele at rs894151 and/or rs12438080. Abbreviations: TTR, time to recurrence; CI, confidence interval; LT, liver transplantation; AFP,
alpha-fetoprotein.
doi:10.1371/journal.pone.0026003.t002
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SNP rs894151 is intergenic between the pleckstrin homology
domain-containing family F member 2 (PLEKHF2) and chromo-
some 8 open reading frame 37 (C8orf37) in chromosome 8q22.
PLEKHF2 encodes an endoplasmic reticulum (ER)-associated
protein. Overexpression of PLEKHF2 enhances tumor necrosis
factor (TNF)-a-induced cellular apoptosis through an ER-mitochon-
drial apoptotic pathway [53]. In 15q26, rs12438080 lies on the
longevity assurance homolog 3 (LASS3) gene, which is evolutionarily
conserved from yeast to mammals [54] and encodes a ceramide
synthase. 8q22 was reported to be associated with elevated expression
of the metastasis gene metadherin (MTDH) with poor clinical
outcomes in breast cancer [55]. Amplification of 15q26 in gastric
cancer cell lines was associated with an up-regulated negative
regulator of cell-cell adhesion [56]. Genome copy-number alteration
and lossof heterozygosity in 15q26 werefound in pediatricmalignant
astrocytomas [57] and breast cancer [58]. We genotyped healthy
individuals and HBV infected patients to evaluate the distribution of
genotypes on the two loci. We found the co-index of the two loci in
either healthy group or HBV group showed significant difference
fromthat in HCCgroup (Supplemental TextS1).Whereas, there was
no difference between healthy group and HBV group. This result
suggested that the two variations may result from acquired somatic
mutations accumulating in the tumor genome.
Patients with AG/GG at rs894151 have larger tumor sizes,
increased tumor number and higher probability of microvessel
invasion,whileworsetumordifferentiationwasassociated withAC/
CC at rs12438080. The genetic variations of the two loci seem to
represent the different features of the progression of HCC. Minor
allele in the two loci may result in more aggressive tumor biologic
behavior via interactions with neighboring tumor associated genes.
Through this biologic change, HCC patients may get poorer
prognosis after LT. However, the precise mechanism by which
rs894151 and rs12438080 are associated with HCC recurrence and
metastasis remains to be clarified and further investigated.
Like most studies focusing on organ transplantation, the sample
size of this study is not very large, which made us to adopt a less
stringent statistical cut-off for microarray analysis. And the sub-
group analyses also came across this problem. This limitation
predispose to a risk of false positive associations. Therefore, our
result need to be further validated using a sufficiently large
independent cohort from different transplantation centers. On the
other hand, since the primary etiology of HCC in China is HBV
infection, we do not have enough patients to be included in the
study at that time. So, our study focused on HBV-related HCC.
The prognostic value of the variation of the two loci shall be
further evaluated for its clinical value across heterogeneous HCC
patients, such as HCV-related or alcohol-related HCC, and
Nonalcoholic steatohepatitis-related HCC.
In conclusion, the present study suggests that HBV-related HCC
patients with allele G at rs894151 and/or C at rs12438080 in
pretransplant plasma circulating DNA may bear an increased risk
for HCC recurrence after LT. In contrast, patients with AA at both
rs894151 and rs12438080 may experience a low recurrence risk,
even in HCC patients exceeding Milan criteria. Genetic variations
of rs894151 and rs12438080 in pretransplant plasma circulating
DNA from HCC patients may predict recurrence after LT.
Supporting Information
Figure S1 Pre-array quality control and distribution of genome-
wide p-values. Pre-array quality control using Mapping PCR test,
PCR products were visualized on 2% agarose gels. Sty and Nsp
represent different restriction enzyme digestions. Samples with
fragments .750 bp indicate good quality for microarray
hybridization. A, samples passing PCR-based QC tests. B, sample
11203 failed the QC test. C, genome-wide p-values of the
Cochran-Armitage trend test. After filtration, 230,802 SNPs were
included for analysis. The chromosomal distribution of P-values
from the trend test is shown. The blue horizontal line represents a
threshold of 10
23 for suggestive significance: 30 SNPs were above
the horizontal line. The inset shows the quantile-quantile (Q-Q)
plots of the observed p-values for association.
(TIF)
Figure S2 Hierarchical clustering of selected SNPs. Each SNP
value was assigned based on the number of minor alleles. A,
Hierarchical clustering of 1272 SNPs with P,.01. Each row
represents an individual SNP and each column represents an
individual tumor sample. B, Hierarchical clustering of 30 SNPs
with P,.001. Each row represents an individual tumor sample
and each column represents an individual SNP. Patients can be
separated into two groups (high-risk or low-risk groups) using 30
top SNPs. The high-risk group had a shorter overall survival time
(C) and time to recurrence (D) than the low-risk group (P,.001).
(TIF)
Figure S3 Kaplan-Meier analysis for recurrence (A) and survival
(B) of patients harboring different numbers of risk alleles. Patients
possessing more risk alleles had a higher recurrent risk and shorter
survival time. The prognostic significance was assessed using
Kaplan-Meier survival estimates and log-rank tests.
(TIF)
Table S1 Clinicopathological characteristics of three cohorts of
HCC patients.
(DOC)
Table S2 Differences in allele frequencies between recurrence
and non-recurrence groups in Training Set 2 (N=102).
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Table S3 Correlation between rs894151, rs1248080, and
clinicopathological characteristics in Training Set (N=102).
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Table S4 Pairwise comparisons of TTR between patients with 0,
1, 2, and 3 risk alleles.
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1, 2, and 3 risk alleles.
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Table S6 Univariate and multivariate analyses of factors
associated with TTR in Validation Set (N=77).
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Table S7 AUC of the co-index and other factors.
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Table S8 Clinicopathological characteristics of HCC patients
beyond Milan criteria.
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Table S9 Kaplan-Meier survival estimates and log-rank tests of
factors associated with TTR and OS in patients exceeding UCSF
criteria.
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Table S10 Kaplan-Meier survival estimates and log-rank tests of
factors associated with TTR and OS in patients within UCSF
criteria.
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